Fractional Exhaled Nitric Oxide as Possible Non - Invasive Biomarker to Assess Obstructive Sleep Apnea Severity
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 200 people, planned
- Started
- 25 May 2026
- Ended
- 1 Oct 2026
- Type of study
- Observational
- Record updated
- 25 August 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Ages Eligible for study: 18 years till 70 years old
- Newly suspected OSA patients with Epworth Sleepiness Scale (ESS) ≥ 10
Who cannot take part
- Recent inhaled or systemic corticosteroids within the pasr 4 weeks
- Any chronic Respiratory disorders other than OSA (asthma, COPD, allergic rhinitis, and atopic diseases)
- Recent respiratory infection less than 4 weeks
- Uncontrolled diabetes \& any chronic debilitating diseases (liver, renal, collagen diseases) Informed Consent will be taken from the participants before clinical examination
- Younger age than 18 years
- Current smokers
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Aim of work
Read full original descriptionShow less
1. Primary aim: Asses correlation between FeNO level, OSA severity 2. Secondary aim: Clarifying FeNO's role as a biomarker to assess airway inflammation, Cut off value prediction to moderate and severe OSA and its potential significance to improve clinical management strategies for OSA patients.
The group in the trial
- • Control group AHI less than 5 \ hour - case groups Milld OSA & moderate to severe OSA
All 200 participants will undergo: * History taking including: Age, sex, occupation, residence, education, and special habits e.g., smoking * Plain chest x ray\& PFT to exclude any other chest diseases (asthma\& COPD) * The participants' Blood pressure, height and weight will be measured, and body mass index will be calculated. * Daytime sleepiness will be assessed by the Epworth Sleepiness Scale and a value of 10 or more denoting as excessive daytime sleepiness. * Full laboratory investigation to exclude any chronic diseases. * Full-night PSG in chest department, Tanta university hospital. * FENO level base line at 9 am after PSG night \& interpretation accordin * After PSG result, cases will be divided in 3 groups * Control group AHI less than 5 \\ hour * Mild OSA group AHI than 5-15 \\ hour * Mod to severe OSA more than 15 \\ hour
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 August 2026